| Patient | Susan B. Anthony |
|---|---|
| Date of birth | 1820-02-15 |
| Identifiers | MRN HR-NI014-SYN-TD; SSN (made up) 000-14-7302 |
| Document date | 1905-03-30 |
| Author | Harold Pemberton, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week heart failure medication safety check. [S]
Miss Anthony returns two weeks after starting furosemide and empagliflozin for newly diagnosed heart failure. She is less breathless and now climbs a flight of stairs with one pause instead of two. Her ankle swelling is gone by morning and returns only slightly in the evening. Her home weights have fallen steadily by about 1.7 kg. She has had no dizziness on standing, no excess thirst, and no genital itching or urinary symptoms since starting empagliflozin. She takes every dose and keeps a weight diary. Her echocardiogram and cardiology consultation were done this morning. [S]
| Element | Detail |
|---|---|
| Interval change | Less breathless on stairs; evening ankle swelling only |
| Weight diary | Down about 1.7 kg over two weeks |
| Medication tolerance | No dizziness, thirst, or genital or urinary symptoms |
| Adherence | Every dose taken |
| NYHA class | II, improved from II to III |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or fatigue beyond her usual after travel |
| Cardiovascular | Positive | Mild evening ankle swelling; no chest pain, palpitations, or orthopnea |
| Respiratory | Positive | Breathless after a flight of stairs; no cough or wheeze |
| Genitourinary | Negative | No dysuria, genital itching, or urgency |
| Neurological | Negative | No dizziness or lightheadedness on standing |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Furosemide 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1905-03-16 to 1905-06-29 | completed | S |
| Empagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1905-03-16 | active | S |
| Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily | One-half tablet by mouth daily | Oral route | 1905-03-30 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1905-03-30 | Body height | 165 | cm | S |
| 1905-03-30 | Body weight | 56.8 | kg | S |
| 1905-03-30 | Body mass index (BMI) [Ratio] | 20.9 | kg/m2 | S |
| 1905-03-30 | Systolic blood pressure | 146 | mm[Hg] | S |
| 1905-03-30 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1905-03-30 | Heart rate | 78 | /min | S |
| 1905-03-30 | Respiratory rate | 18 | /min | S |
| 1905-03-30 | Body temperature | 36.6 | Cel | S |
| 1905-03-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1905-03-30 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 1905-03-30 | Potassium [Moles/volume] in Serum or Plasma | 3.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1905-03-30 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1905-03-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1900)/1.73 sq M | 58 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1905-03-30 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 1905-03-30 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 1905-03-30 | Left ventricular Ejection fraction | 62 | % | 50-70% | Normal | S |
| 1905-03-30 | Left atrial End-systolic volume (by US.2D+Calculated by biplane method of disks)/Body surface area | 42 | mL/m2 | <=34 mL/m² | High | S |
| 1905-03-30 | Heart valve E velocity/Annulus E wave by US | 16 | {ratio} | <=14 | High | S |
Vital signs recorded on 1905-03-30; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert, comfortable, speaking easily |
| Neck | Jugular venous pressure 7 cm, down from 10 cm at intake |
| Lungs | Clear; the basal crackles heard at intake are gone |
| Heart | Regular rhythm; S4; no murmur |
| Extremities | Trace ankle edema, down from 2+ at intake |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Heart failure with preserved ejection fraction, NYHA class II to III at diagnosis; synthetic modern diagnosis linked to the documented 1785 heart failure | active | confirmed | I50.32 | S — Synthetic diagnosis confirmed by echocardiogram in the modern episode; the 1906 cause of death remains D. |
| Hypertensive heart disease with heart failure | active | confirmed | I11.0 | S — Synthetic diagnosis; no blood pressure from her lifetime is recorded in the cited sources. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel with magnesium | 1 to 2 weeks after starting or changing therapy; every 3 to 6 months when stable | Completed today | Two weeks after starting furosemide and empagliflozin. Sodium, potassium, creatinine, and magnesium normal; eGFR 58, a small expected fall |
| Imaging | Transthoracic echocardiogram | At diagnosis; repeat only with unexplained change | Completed today | Ejection fraction 62 percent, left atrial volume index 42 mL/m², E/e' 16: heart failure with preserved ejection fraction |
| Examination | Blood pressure, heart rate, weight, jugular venous pressure, edema, lungs | Every visit | Completed today | Weight down 1.7 kg; jugular venous pressure and edema improved |
| Survey | NYHA functional class | Every visit | Completed today | Class II |
| Survey | KCCQ-12 | Baseline, then every 3 to 6 months | Up to date | Baseline 52 at intake; next at the three-month review |
| Referral | Cardiology evaluation for specific causes | At diagnosis | Completed today | Seen today. Cardiac amyloidosis is not suspected: septal thickness 11 mm, voltage criteria for left ventricular hypertrophy on the ECG, and no carpal tunnel or neuropathy |
| Medication safety | SGLT2 inhibitor tolerance | Each visit while starting | Completed today | No volume depletion, genital infection, or urinary infection |
| Self-management | Daily weight diary | Every visit | Completed today | Reviewed; she records every morning |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine PCV20; Respiratory syncytial virus vaccine, single dose [S]
Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026)
Follow-up: Basic metabolic panel in one to two weeks after starting spironolactone. Heart failure review in three months. Next scheduled visit 1905-06-29: three-month heart failure and blood pressure review. [S]